Brought to you by

Serono licenses cancer candidate from Micromet
05 Dec 2006
Executive Summary
Micromet (antibody therapeutics for cancer, inflammation, and autoimmune conditions) and Serono SA have entered into an agreement to further develop Micromet's MT201 (adecatumumab), a fully human monoclonal antibody that targets the epithelial cell adhesion molecule (Ep-CAM) to fight various types of cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com